PROGRAMME 10:30 11:00 Registration and coffee 11:00 11:10 Welcome address: Prof. William Gallagher, Director of the UCD Conway Institute, Professor of Cancer Biology at UCD and Director of BREAST-PREDICT 11:10 12:10 Keynote talk: Lifestyle Factors in Breast Cancer Dr. Pamela Goodwin, Director of Mount Sinai Hospital's Marvelle Koffler Breast Centre (Toronto, Ontario) 12:10 12:50 Session 1: Exercise Interventions for Cancer Patients Chair: Prof. William Gallagher 12:10 12:30 Exercise in Cancer Survivorship Prof. Juliette Hussey, Professor in Physiotherapy and Vice President for Global Relations in Trinity College Dublin 12:30 12:50 Technology Enabled Rehabilitation in Cancer - Examples from the CATCH Programme Prof. Brian Caulfield, Professor of Physiotherapy, UCD School of Public Health, Physiotherapy & Sports Science and Lead Investigator at the Insight Centre for Data Analytics 12:50 13:30 Lunch 13:30 14:30 Session 2: Lifestyle and Metabolic Factors in Cancer: Mechanisms to Outcome Chair: Dr. Darran O Connor, Senior Lecturer (Clinical Pharmacology) at the Royal College of Surgeons in Ireland 13:30 13:50 The Influence of Lifestyle and Metabolic Factors on Colorectal Cancer Development Dr. David Hughes, UCD School of Biomolecular & Biomedical Science, UCD Conway Institute 13:50 14:10 FKBPL: A Common Factor in Cancer and Obesity Prof. Tracy Robson, Professor and Head of Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland 2
14:10 14:30 Obesity: its Links with Altered Metabolism and Treatment Response in Oesophageal Cancer Prof. Jacintha O Sullivan, Professor in Translational Oncology, Trinity Translational Medicine Institute (TTMI), St. James s Hospital 14:30 15:30 Session 3: Nutritional Intervention in Cancer Chair: Prof. William Gallagher 14:30 14:50 Dietary Modulation of Metabolic-Inflammation Relevance to Cancer Risk Prof. Helen Roche, Professor of Nutrigenomics, UCD Conway Institute, University College Dublin 14:50 15:10 Optimising Nutritional Status Throughout the Cancer Trajectory - the Oesophageal Cancer Model Dr. Suzanne Doyle, Lecturer in Nutrition and Dietetics, Dublin Institute of Technology and Trinity College Dublin 15:10 15:30 Diet and Cancer: Can Technology Help? Dr. Claire Timon, Senior Researcher, Centre for Applied Research in Connected Health (ARCH) 15:30 15:50 Coffee break 15:50 16:10 Session 4: Non-Surgical Approaches to Cancer Management Chair: Prof. William Gallagher 15:50 16:10 Non-Surgical Management of Endometrial Cancer in the Obese Patients Prof. Donal Brennan, Professor of Gynaecological Oncology, UCD; Consultant Obstetrician and Gynaecological Oncologist at Mater Misericordiae University Hospital/ National Maternity Hospital / St Vincent s University Hospital 16:10 16:30 Session 5: Survivorship Chair: Prof. William Gallagher 16:10 16:30 Prosper: A multi-disciplinary approach to supporting men diagnosed with prostate cancer and beyond Prof. William Watson, Professor of Cancer Biology, UCD School of Medicine and Medical Science 16:30 17:00 Discussion and closing remarks 3
SPEAKERS Dr. Pamela Goodwin Director of Mount Sinai Hospital's Marvelle Koffler Breast Centre (Toronto, Ontario) Dr. Pamela Goodwin focuses her research on lifestyle and related factors and their impact on breast cancer patient survival rates. As a clinician and Director of Mount Sinai Hospital's Marvelle Koffler Breast Centre, Dr. Goodwin shares her research insights with patients and provides support to improve the overall health of breast cancer survivors. Dr. Pamela Goodwin has been actively involved in research relating to host factors in breast cancer for the past 25 years. Early in her career, she became intrigued with the possibility that host (patient-related) factors, especially obesity, might impact outcomes of women diagnosed with breast cancer. She began a program of research that has focused on the role of these factors, including obesity, nutrition, exercise and related factors in the clinical course of breast cancer. She has led a number of studies which investigate the complex interactions between body size, nutrition, exercise and physiologic mediators such as insulin, IGF-I and vitamin D, examining the impact of these factors on risk and survival of women diagnosed with breast cancer. Dr. Goodwin has expanded this work to investigate the status of long-term breast cancer survivors and the influences of hereditary factors, vitamin D and metformin on breast cancer outcomes. She currently leads a large international Phase III trial (NCIC MA.32) which examines the impact of an insulin lowering drug, metformin, on breast cancer outcomes and has an active translational research program examining the interface between host factors and tumor biology in both early and advanced breast cancer. She leads the Hold Em for Life Translating Research Discoveries into Breast Cancer Cures Program at Mount Sinai Hospital and the Princess Margaret Cancer Centre. 4
Prof. Juliette Hussey Professor (Physiotherapy) and Vice President Global Relations at Trinity College Dublin Prof. Hussey has been in Trinity for over 20 years and was head of the discipline of Physiotherapy from 2003-2014. She is currently the Vice President for Global Relations in Trinity College Dublin, The University of Dublin. Prof. Hussey leads a group working in the area of exercise rehabilitation in patients with cancer. Her research is translational and is aimed at scientifically improving exercise prescription to optimise therapeutic responses. This includes evaluating means of improving physical capacity preoperatively to reduce postoperative morbidity for patients undergoing complex cancer surgery. A challenge in the area of exercise and cancer is to determine underlying mechanisms and her group is working with clinical scientists in this respect. Her group is also part of Movember Global Action Plan 4 a randomised controlled trial examining exercise in men with advanced prostate cancer. Prof. Brian Caulfield Professor of Physiotherapy, UCD School of Public Health, Physiotherapy & Sports Science and Lead Investigator at the Insight Centre for Data Analytics Prof. Brian Caulfield is the Lead Investigator in Ireland s industry led Connected Health Technology Centre, ARCH and is a Director of Ireland s largest research centre, the INSIGHT centre for Data Analytics, where he leads the Connected Health research programme. A physiotherapist by training, he is also Dean of Physiotherapy at UCD. Dr. Caulfield is a champion for a Connected Health ecosystem in Ireland and has forged strong relationships with key clinicians, industry leaders, policy makers and research groups to drive advances in the field. Previously, he was a PI in the CLARITY Centre for Sensor Web Technologies and Director of the TRIL Centre, a research centre focused on technologies for 5
independent living, which was funded by GE and Intel. As well as these companies, he has worked with a range of multinational and start-up companies to deliver innovative technology enabled solutions for areas such as rehabilitation medicine, COPD, and gerontology. Dr. David Hughes UCD School of Biomolecular & Biomedical Science, UCD Conway Institute The research of Dr David Hughes focuses on nutritional, genetic and microbial epidemiology of various cancer sites. He currently leads large prospective cohort studies in the European Prospective Investigation of Cancer and Nutrition (EPIC; based at the International Agency for Research on Cancer in Lyon, France) of the influence of bacterial antigens and nutritional status of micronutrient minerals selenium, zinc, copper, calcium, and iron on colorectal, liver, breast, and gastric cancer risk. Recent findings include that antigens to Streptococcus gallolyticus in advance of cancer onset are associated with colorectal cancer development that pre-diagnostic selenium status is associated with colorectal and liver cancer risk and that pre-diagnostic zinc and copper concentrations are associated with liver and colorectal cancer risk. Principal funders of his work in recent years have been the Irish Health Research Board (HRB), including three HRA awards since 2011 and one of the inaugural Investigator Led Project (ILP) awards in 2017, the World Cancer Research Fund (WCRF), and various funders for the EPIC project. Prof. Tracy Robson Professor and Head of Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland Prof Robson has a major programme of research aimed at the identification and functional characterisation of genes that alter tumour response to anti-cancer agents. In particular, she cloned and is characterizing a novel human gene, FKBPL. 6
Together with Almac, she has led the development of therapeutic peptide derivatives (AD-01 and ALM201) based on FKBPL s active anti-angiogenic domain. Based on the robust efficacy and excellent safety profile, ALM201, a first-in-class FKBPL-based anti-angiogenic therapeutic peptide has completed formulation and toxicology testing and has entered phase I/II cancer clinical trials. Prof Robson continues to interact with Almac towards the successful clinical development of this drug and is a translational co-investigator on the Phase I/II clinical trial. Over the last 15 years she has attracted significant funding ( >7.5 million) from UK research councils, MRC & BBSRC, and national charities, Cancer Research UK, Breast Cancer Now, Prostate Cancer Charity, HPSS R&D Office, and numerous other cancer charities. Prof. Jacintha O Sullivan Professor in Translational Oncology, Trinity Translational Medicine Institute (TTMI), St. James s Hospital Prof. Jacintha O'Sullivan is the Director of the MSc in Translational Oncology, Education lead for the Trinity, St. James s Cancer Institute and the Education and Outreach Coordinator in TTMI. Currently, Prof O'Sullivan directs a translational gastrointestinal (GI) research team in the Trinity Translational Medicine Institute (TTMI) in collaboration with clinical and surgical colleagues. She utilises well established bio-banking structures to drive this GI translational research program. Prof. O'Sullivan's current translational research themes include: Development of diagnostic platforms to stratify cancer risk and response to targeted therapies for gastrointestinal diseases. Development of novel patented therapeutics to be used in the neoadjuvant and adjuvant treatment setting for gastrointestinal cancer patients (Colorectal and Oesophageal cancers). Elucidating how the tumour microenvironment cross talks to the immune system in GI patients. Importance of metabolism, inflammation and obesity in driving disease progression and in regulating treatment response in GI diseases. 7
Prof. Helen Roche Professor of Nutrition and Nutrigenomics, UCD Conway Institute, University College Dublin Prof. Roche is Vice President for Research, Innovation and Impact at the College of Health and Agricultural Sciences at UCD; Scientific Advisory Board Chair for the European Healthy Diet Healthy Life, Joint Programming Initiative research programme and Fellow of the International Union of Nutritional Sciences. Prof. Roche leads the Nutrigenomics Research Group at the UCD Conway Institute / UCD Institute of Food & Health. Nutrigenomics uses state-of-the-art omics technologies to gain a greater understanding of the molecular effects of nutrition on health. Her team has a specific interest in Personalised Nutrition, identifying and understanding the molecular basis of responsiveness and efficacy of more targeted lifestyle interventions in population sub-groups. Her research team explores different aspects of the interactions between food related, nutritional stressors, metabolism and inflammation within the context of obesity, insulin resistance type 2 diabetes and related conditions. She leads / is co-pi within several national and international research programmes. Dr. Suzanne Doyle Lecturer in Nutrition and Dietetics, Dublin Institute of Technology and Trinity College Dublin Dr. Doyle was appointed Lecturer in Nutrition and Dietetics in Dublin Institute of Technology in 2016 and holds Adjunct Lecturer status with Trinity College Dublin. In this role, she lectures on the BSc Human Nutrition and Dietetics, BSc Public Health Nutrition and MSc Translational Oncology programmes. 8
Dr. Doyle s current research focuses on investigating rehabilitative needs and strategies in cancer patients as well as the impact of sarcopenia on cancer outcomes. Alongside dietetic research, she worked as a clinical dietitian in St James s Hospital prior to her appointment in DIT, gaining experience in oncology, surgery, geriatric and orthopaedic rotations. Dr. Doyle is the Chair of the Scientific and Research Steering Group within the Irish Nutrition and Dietetic Institute, Council member of the Nutrition Society and the Education Representative of the Dietitians Registration Board of CORU. Dr. Claire Timon Senior Researcher, Centre for Applied Research in Connected Health (ARCH) Dr Claire Timon holds a BScAg in Food Science from University College Dublin and a PhD in Human Nutrition from The University of Sheffield. Her PhD and post-doctoral training focused on the development and validation of diet and health assessment technologies for both research and national surveillance purposes. In 2017, Dr Timon successfully attained an SFI Industry Fellowship focusing on the development of a personalised dietary advice system and the commercialisation of a dietary assessment technology Foodbook24, working between the UCD Institute of Food and Health and an industry partner Creme Global. Dr Timon currently works in the Centre for Applied Research in Connected Health (ARCH) as a senior researcher and her research interests concern: technological approaches to the assessment of diet and health, connected health solutions for dietetic practice and the potential of digital health technologies to provide personalised diet and lifestyle support for cancer patients and individuals with chronic disease. 9
Prof. Donal Brennan Professor of Gynaecological Oncology, UCD; Consultant Obstetrician and Gynaecological Oncologist at Mater Misericordiae University Hospital, National Maternity Hospital & St Vincent s University Hospital Prof. Brennan was awarded a PhD in cancer biology by University College Dublin in 2008. He undertook specialist training in Obstetrics and Gynaecology working in the National Maternity Hospital, Cork University Maternity Hospital, The Coombe and The Rotunda Maternity hospitals. His main research interests are in biomarker development, tumour inflammation and obesity related carcinogenesis. He has received several awards for his research and was awarded European Young Researcher of the Year in 2010. He has over 60 peer-reviewed publications and has been named on 6 international patents. In 2012 he relocated to Brisbane to undertake subspecialist training in gynaecological oncology in the Queensland Centre for Gynaecological Cancer and also completed a fellowship in general and colorectal surgery. During his time in Brisbane he was a visiting scientist at the QIMR-Berghofer Medical Research Institute. His main surgical interests are laparoscopic pelvic surgery and cytoreductive surgery for advanced ovarian cancer. He also enjoys caring for obstetric patients, particularly those with complex surgical histories. Prof. William Watson Professor of Cancer Biology, UCD School of Medicine and Medical Science, University College Dublin Professor Watson received his PhD degree in Biochemistry from the Department of Biochemistry, University College Cork in 1995. He then undertook his post-doctoral research in University of Toronto and the Toronto General Hospital in Canada, before returning in 1997, to the Department of Surgery, Mater Misericordiae University Hospital as a college Lecturer in University College 10
Dublin. He is now Full Professor of Cancer Biology in the UCD School of Medicine, University College Dublin. Apart from his undergraduate and post-graduate teaching responsibilities, he has an active internationally recognised research group. As a translational biologist based in the Conway Institute he utilises latest technologies to study cellular and molecular pathways and clinical collaboration through the Prostate Cancer Research Consortium, iprospect and Opti-Predict to expand the understanding of the initiation and progression of prostate cancer in order to identify diagnostic and prognostic biomarkers and therapeutic sites for manipulation. These studies have led to other International collaborators as part of the Movember Global Action Plan and ToPCaP. 11